Responses
Clinical/translational cancer immunotherapy
Original research
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
Compose a Response to This Article
Other responses
No responses have been published for this article.
